These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26659106)

  • 21. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.
    Borup R; Traulsen JM; Kaae S
    Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European Medicines Agency pledges to publish clinical reports.
    Watson R
    BMJ; 2014 Oct; 349():g6086. PubMed ID: 25294699
    [No Abstract]   [Full Text] [Related]  

  • 23. Regulatory Aspects of Traditional Indian Medicines (TIM) in India and in International Purview.
    Sharma AK; Pundarikakshudu K
    J AOAC Int; 2019 Jul; 102(4):993-1002. PubMed ID: 30609950
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
    Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
    Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
    D'Hooghe T
    Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulating pharmaceutical advertising: what will work?
    Shapiro MF
    CMAJ; 1997 Feb; 156(3):359-61. PubMed ID: 9033416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation.
    Zalesky CD
    J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Removal of Certain Time of Inspection and Duties of Inspector Regulations for Biological Products. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2018 Jan; 83(18):3586-9. PubMed ID: 29372981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of current good manufacturing practices and emission regulations and guidances on the discharge of pharmaceutical chemicals into the environment from manufacturing, use, and disposal.
    Velagaleti R; Burns PK; Gill M; Prothro J
    Environ Health Perspect; 2002 Mar; 110(3):213-20. PubMed ID: 11882470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory agencies, pharmaceutical information and the Internet: a European perspective.
    Bauschke R
    Health Policy; 2012 Jan; 104(1):12-8. PubMed ID: 22101089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Japanese Regulatory Frameworks for Post-Marketing Management of Pharmaceutical Products.
    Takamura K; Tachibana K; Kusakabe T; Nakai K; Tsutsumi Y; Kondoh M
    Pharm Res; 2020 Jun; 37(7):122. PubMed ID: 32514811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of biotechnology products in the global pharmaceutical market: the case of the European community and the United States.
    Hakim Z; Kucukarslan S
    Clin Ther; 1993; 15(2):442-58; discussion 432. PubMed ID: 8519050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Data Integrity in Global Clinical Trials: Discussions From Joint US Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency Good Clinical Practice Workshop.
    Khin NA; Francis G; Mulinde J; Grandinetti C; Skeete R; Yu B; Ayalew K; Cho SJ; Fisher A; Kleppinger C; Ayala R; Bonapace C; Dasgupta A; Kronstein PD; Vinter S
    Clin Pharmacol Ther; 2020 Nov; 108(5):949-963. PubMed ID: 31958142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks.
    Tsukamoto K; Carroll KA; Onishi T; Matsumaru N; Brasseur D; Nakamura H
    Clin Ther; 2016 Mar; 38(3):574-81. PubMed ID: 26869192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparing for an FDA preapproval inspection.
    Blackmer RA
    Qual Assur; 1994 Dec; 3(4):389-403. PubMed ID: 7613749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Legislative and non-legislative regulations concerning Rx drug advertisement in the European Union and the United States--comparative analysis.
    Czerw A; Religioni U
    Acta Pol Pharm; 2012; 69(4):779-87. PubMed ID: 22876622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.